Emcure Pharmaceuticals Limited — PPTs, 12-06-2026: Investor Presentation

**1. Business Performance:** Emcure posted robust FY26 results: revenue hit ₹9,204 Cr (+16.6% YoY). Profitability surged, with EBITDA margin at 19.4% and Adjusted PAT margin at 10.9%. Growth was balanced, driven by domestic and international markets, especially complex product sales.

**2. Growth Drivers or Strategy:** Growth drivers include a strong R&D pipeline (differentiated biologics, complex injectables), strategic in-licensing (Sanofi, Novo Nordisk, Roche), and acquisitions like Zuventus Healthcare (₹724.9 Cr). India's expansion into Consumer & Dermatology segments is key.

**3. Recent Developments:** Emcure launched Poviztra® (semaglutide injectable) and finalized the Zuventus Healthcare acquisition. Key brand partnerships in India strengthened, including new agreements with Novo Nordisk and Roche.

**4. Key Financial Metrics:** FY26 highlights: Revenue ₹9,204 Cr (+16.6% YoY), EBITDA ₹1,789 Cr (19.4% margin), Adj. PAT ₹1,008 Cr (10.9% margin). Return on Capital Employed (ROCE) climbed to 23.8%.

**5. Management Commentary / Outlook:** Management anticipates consistent mid-to-high teens revenue growth and ongoing margin expansion. A diversified portfolio and future-ready complex product pipeline are expected to drive sustained long-term growth.